🇺🇸

US SEC Filing Intelligence

· daily

US Earnings Financial Results SEC Filings — October 13, 2026

Across 31 US SEC filings for the period ending October 13, 2026, the dominant theme is sharp dispersion between one-time accounting items and underlying operating health. Several headline net income swings (Nurix Therapeutics, Worthington Steel, Shreya Acquisition, Advanced Biomed, Eagle Nuclear) were driven by license revenue, acquisitions, derivative or warrant fair-value gains, or disposal gains rather than core operations. Operating momentum is strongest among industrial and healthcare-adjacent names with real revenue growth (Park Aerospace +26.9% YoY sales, Solitron Devices +41.9%, AZZ +16.7%, Escalon +5.7%), while a large cluster of micro-cap shells and going-concern filers (Cybriatech, Zhanling, ANVI Global, Yan Chuang, Birdie Win, Wenyuan, Okmin) show zero or near-zero revenue, rising related-party funding, and widening stockholders' deficits. Balance-sheet stress is the second major theme: Domino's carries $1,326.8M of debt reclassified to current, US Nuclear's shareholders' deficit deepened to $(740.1)M, Worthington's long-term debt rose to $1,654.8M after a large acquisition, and Lunai Bioworks reports under one month of cash. Among larger filers, interest-rate and derivative sensitivity is visible at National Rural Utilities (adjusted net income -7.5%) and in Domino's investment impairment. Net-net, the filings argue for quality screening: separate recurring operating earnings from non-recurring gains before acting on headline EPS, and treat going-concern language, related-party dependence, and convertible dilution as primary risk gates.

31 high priority 31 total filings
· daily

US Executive Compensation Proxy SEC Filings — October 13, 2026

This stream covers 20 DEF 14A proxy filings dated around October 13, 2026, and the enriched data is largely absent: nearly all filings report no period-over-period financial results, no insider transaction values, and no forward guidance. The governance content is the substance here, and it clusters into three recurring themes: Nasdaq listing and dilution remediation (Upexi, GT Biopharma, Healthcare Triangle, Health In Tech, Adagio Medical), reverse splits and authorized-share expansions, and concentrated voting control (Galectin, Health In Tech dual-class, Marathon Bancorp's 10% voting cutoff). Upexi is the single most material filing, with Nasdaq Staff having found two convertible note issuances in violation of Rule 5635(a) and up to ~42 million shares potentially issuable against a company whose listing is at stake. Several filings are routine director elections and auditor ratifications with no investment signal. Mutual-fund and closed-end fund proxies (Principal Funds, Principal ETFs, RMB Investors Trust, Japan Smaller Cap, SRH Total Return) concern fund governance rather than executive pay, and are treated as out of scope for this compensation-focused stream. Overall, the batch points to dilution pressure among micro-cap, Nasdaq-listed issuers, and should be read as a governance-risk digest rather than an executive-compensation one.

20 high priority 20 total filings
· daily

US IPO Pipeline SEC S-1 Filings — October 13, 2026

All four filings are Form S-1 registration statements dated October 13, 2026, spanning a small convertible-financed company, a Cayman SPAC, a Cayman SPAC-style unit offering, and an operating industrial/electronics company with an April 2026 IPO reference. None of the filings contains readable period-over-period financial figures, insider transaction data, or forward guidance in the supplied excerpts, so no quantitative YoY or QoQ trend can be verified from the enriched fields; sentiment is neutral across all four and materiality ranges from 4/10 to 6/10. The dominant portfolio theme is the SPAC and blank-check structure: two of four filings (Apex Treasury Corp II and EuroSPAC Acquisition Corp.) are shell vehicles with no operating business, so their value depends entirely on eventual target selection and redemption dynamics. The most substantive operating-company signal is Arxis, Inc., which references a serial acquisition program (four deals from 2024 to 2026) and aerospace/defense end markets, though its IPO-timing claim (April 16, 2026) needs reconciliation with an October 2026 S-1. Alternative Ballistics Corp shows heavy reliance on related-party convertible debt, a financing profile that warrants scrutiny before any allocation.

4 high priority 4 total filings
· daily

US SEC Trading Suspension Halt Orders — October 13, 2026

All four filings in this trading-suspension, delisting, and regulatory-halt stream are Nasdaq or NYSE listing-compliance actions dated around October 6-8, 2026, and every one falls squarely within scope. Two filings (ClearOne and Newton Golf) involve stockholders' equity deficiencies under Nasdaq Rule 5550(b)(1) with imminent suspension or delisting dates (October 15 and October 19, 2026), while Equus faces a sub-$1.00 price deficiency on the NYSE and CN Healthy Food Tech has received a Panel decision permitting continued listing under a one-year monitor. The filings provide no period-over-period financial metrics, guidance, insider transactions, or capital allocation data, so quantitative trend analysis is not possible from this set; the signals below rest on event timing and regulatory status. The dominant theme is that a fundamental capital/equity shortfall is driving the most acute delisting risk, with the two Nasdaq equity-deficiency cases carrying the highest materiality and nearest deadlines. Investors should treat the October 13-20 window as the critical catalyst period for this group.

4 high priority 4 total filings
· daily

US Executive Officer Management Changes SEC — October 13, 2026

This Oct 13, 2026 digest covers 27 executive and director change filings, the bulk of them 8-Ks with no quantitative financial results attached, so the enriched period-over-period, insider-activity, and capital-allocation fields are largely empty across the stream. The dominant pattern is CFO and principal accounting officer turnover (Duos, Mueller Water, SAIC, Dauch/American Axle, Genworth, Lazard, Peloton, Crescent Private Credit, Expand Energy), with several finance-function reshuffles happening in the same October window. Governance stress is concentrated in small caps, most notably Nuvve's simultaneous exit of its Audit and Compensation Committee chairs, while larger names show orderly succession (Harmony, CSX, Danaher, Merck). The single most material item is Bausch + Lomb's abrupt CEO exit with Chairman Appio stepping in as interim CEO, coupled with a pre-announced guidance raise based on preliminary Q3 results. Most other filings explicitly disclaim disagreement with management, so the market read-through is mainly about bandwidth and execution timing rather than hidden accounting issues.

27 high priority 27 total filings
· daily

US Corporate Board Director Changes SEC Filings — October 13, 2026

This digest covers 27 SEC 8-K filings dated 2026-10-13 under the USA Board Room Changes stream (Officer Change, Director Change, Board Change). Nearly all filings are governance events rather than financial disclosures: the filings carry no period-over-period revenue, margin, or ratio data, so trend analysis is limited to the few that include guidance or capital-related items. The dominant pattern is a cluster of CFO, Chief Accounting Officer, and Principal Accounting Officer transitions (Mueller Water, SAIC, Dauch/American Axle, Genworth, Lazard, Peloton, Crescent Private Credit, Expand Energy, Duos), several of which are interim or retroactive arrangements and warrant closer governance review. The most material developments are Bausch + Lomb's abrupt CEO exit with an interim CEO who is also Bausch Health's CEO, alongside a guidance raise, and Nuvve's simultaneous resignation of its Audit and Compensation Committee chairs, which is the most negative governance signal in the set. Shareholder dissent was visible at MillerKnoll, where roughly 14.5% of votes cast on its incentive plan were against, versus under 3% on other proposals. Forward-looking items are sparse, with Harmony Biosciences the only clearly reaffirmed guidance (WAKIX net revenue $1.0B to $1.04B for 2026) and Bausch + Lomb expecting an EBITDA guidance raise with results on October 28.

27 high priority 27 total filings
· daily

USA Insider Trading Pulse — October 13, 2026

This digest covers 50 SEC Section 16 insider filings dated 2026-10-13, all within the US insider-trading scope. Activity is dominated by routine equity compensation (restricted stock units, phantom units, option grants and tax withholdings) at Progressive, Soligenix, Kulicke & Soffa, Nano-X, FULLER H B and others, which carries limited signal value on its own. The meaningful open-market activity is concentrated in purchases: Borr Drilling director Troim Tor Olav (~$11.8M), Saratoga Investment CEO Oberbeck (~$445K across two tranches), PEDEVCO 10% owner Kukes (~$1.91M), Gold.com's 10% holder Tether (~$1.28M) and Uxin CEO Dai Kun. On the sell side, Medline's 10% holder GIC sold roughly $275M of Class A stock, the largest single transaction in the batch, while Saba Capital trimmed positions across closed-end funds. Several insider sales were executed under Rule 10b5-1 plans, which dampens their information content. Cross-filing, the dominant pattern is insider accumulation at small caps versus institutional distribution at large holders.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — October 13, 2026

Across the 21 filings in this window, the dominant theme is SPAC lifecycle stress in the M&A stream: deadline-driven extensions, heavy redemptions, delistings, and terminated or restructured deals. Quetta Acquisition Corp appears three times, with a Nasdaq delisting notice and trading suspension effective October 14, 2026, a 96% redemption leaving only 149,860 shares, and a one-month trust extension to November 10, 2026. Redemption pressure is also visible at Black Hawk (about 50% of shares redeemed at ~$12.04) and Starry Sea (4.28M public shares tendered, forcing a meeting postponement to October 19). Copley Acquisition's mutual termination with Ignite Proteomics is the clearest negative deal-break event, while Alaunos/Velaris ($350M PIPE, preclinical pipeline) and Dot Ai/Envoy (all-stock, BladeRanger majority control) are large, high-dilution transactions with significant execution risk. The most substantive operating data comes from the Sizzle II/Trasteel disclosures, which show H1 2026 revenue +40.0% YoY, EBITDA +80.8% YoY, and reaffirmed FY2026 guidance, though all figures are unaudited management accounts. Several filings (Eureka, M Evo II, Iron Horse II, Quetta extension) are procedural and carry little investable signal; the enriched data for these filings does not contain period comparisons, insider activity, or capital allocation metrics, so conclusions are limited to deal structure and governance. Overall, the window reads as a late-cycle SPAC market where sponsor economics, redemption rates, and financing dilution matter more than headline valuations.

21 high priority 21 total filings
· monthly

US Pre-Market SEC Filings Roundup — October 13, 2026

The overnight US SEC filing stream for 2026-10-12 to 2026-10-13 is dominated by corporate-event and capital-structure disclosures rather than broad earnings, with the most material items concentrated in listing risk, restatements, and M&A. Nasdaq delisting pressure is visible at ClearOne (hearing deadline October 15, suspension October 19 if no hearing) and Quetta Acquisition (delisting effective October 14), while SPAC extension and redemption activity appears at Starry Sea, Quetta, and IX Acquisition. Accounting integrity is a theme, with EON Resources restating FY2025 DD&A (loss reduced from $10.1M to roughly $7.5M), Fusion Fuel Green withdrawing reliance on FY2025 audited and pro forma figures, and EON's 10-K/A showing PV-10 down about 82% YoY. Period-over-period results are strongest at ImmuCell (Q3 sales +46% YoY, 9-month +27.8%) and ASE Technology (Q3 revenue +44.8% YoY), while Domino's shows a mixed picture: Q3 revenue +3.4% and EPS +12.7% against U.S. same-store sales of only +0.3%, a stockholders' deficit of $3,955.1M, and $1,326.8M of debt reclassified as current. Transformational deals include IonQ's up-to-$1.3B all-stock Elisity acquisition and Humana's CenterWell joint venture with HPS, which removes a put-option liability while GAAP EPS guidance is flagged as subject to change. Insider activity is light: a Sea Ltd CCO/GC sold shares under a 10b5-1 plan, and no open-market insider buying was disclosed in the stream.

18 high priority 32 medium 50 total filings
· daily

Global High-Priority Regulatory Events — October 12, 2026

The 30 filings for the Global High Priority Market Events stream are dominated by Indian SEBI and listed-company disclosures, with the bulk concentrated on open offers, insolvency resolutions, and intra-group or subsidiary acquisitions rather than large-cap US takeovers. Several clusters stand out: a live mandatory open offer for Inani Securities (Aikyam acquiring 56.92% at Rs. 60, with a parallel public offer for 26%), multiple Power Grid and Ceigall TBCB transmission SPV acquisitions completed on 12 October 2026 at roughly Rs. 18-20 Crore each, and a rejected RBI approval that forced withdrawal of the Brijlaxmi Leasing open offer. Period-over-period data is sparse because most filings are procedural, but where figures exist the growth pattern is mixed: Shakti Energy Solutions grew turnover about 10.4% YoY (Rs. 216.53 to 239.11 Crore), while Shakti EV Mobility's Rs. 372.73 to 2,425.41 Lakh jump and Minda's Sunsure target's turnover rise (Rs. 716.20 to 963.75 Lakh) came alongside losses at the target. The most material item is the Bank of India disclosure of a Rs. 575.40 crore fraud-classified NPA at Future Enterprise, fully provisioned, which points to contagion risk across the Future Group complex. Governance and approval risk is the common thread: several transactions remain conditional on SEBI, RBI, CERC, NCLT or exchange approvals, and at least one (Ventive Hospitality) is being challenged by appeal.

30 high priority 30 total filings
· daily

Federal Construction & Infrastructure Contracts — October 11, 2026

This digest covers a single federal construction and infrastructure award totaling $58,870,322 in obligation, with a base-plus-options ceiling of $59,034,891. The contract is civilian, with zero defense-related awards in the period, and reflects a Department of Veterans Affairs theme of facility infrastructure replacement. The award went to ESA SOUTH, INC., a Florida-based Service Disabled Veteran Owned Small Business, under a set-aside, to replace Air Handling Units 2 and 3 under contract 36C248. The highest-conviction read is that this is a durable, project-based VA infrastructure award with a defined schedule through February 25, 2028, but the signal is neutral because the reported $0 outlay means realized revenue and execution progress cannot be confirmed from the data. The key watch item is whether outlays begin to accrue, and whether any modification shifts the obligation or end date.

1 total filings
· daily

DHS Homeland Security Contracts — October 11, 2026

This digest covers a single DHS contract record totaling $31,043,009 in obligation, with zero defense-related awards and a civilian-only profile. The award is a firm-fixed-price food services contract from DHS's Federal Law Enforcement Training Center to The New Mexico Commission for the Blind, a New Mexico state government entity rather than a publicly traded company. Base-plus-options value is $71,568,849, with $26,649,087 already outlayed, and performance runs from 2023-10-01 through a current end date of 2027-09-30 (potential end 2031-09-30). The highest-conviction read is that this is a low-materiality, neutral award with no direct equity exposure identified in the data. The key watch item is option exercise activity that would move obligations from $31,043,009 toward the $71,568,849 ceiling, since that determines whether the award scales meaningfully over time.

1 total filings
· daily

VA Healthcare & Services Contracts — October 11, 2026

This digest covers a single VA Healthcare & Services contract totaling $58,870,322 in obligations, with zero defense-related awards, so the entire $58.87M sits in the civilian bucket. The dominant theme is Department of Veterans Affairs facility infrastructure, specifically the replacement of Air Handling Units 2 and 3 under a firm fixed-price award to ESA SOUTH, INC. The highest-conviction read is that the award is a clean, single-project infrastructure win for a Service Disabled Veteran Owned Small Business, but the record is neutral overall (signal strength 3/10, materiality 3/10) because the contract is project-based rather than recurring and no outlays are yet recorded. The key watch item is whether the reported $0 outlayed begins to increase through the October 2022 to February 25, 2028 performance period, since that is the only near-term evidence of execution. The aggregate average signal strength of 3.0/10 reflects a limited, low-materiality sample rather than a broad sector read.

1 total filings
· daily

New Federal Contractors — October 11, 2026

Six new federal contract awards totaling $241,728,413 were recorded for the period October 11, 2026, all with civilian agencies and none defense-related (0/6). The dominant theme is civilian-agency service and infrastructure work spread across the Department of Veterans Affairs, Department of Labor, HHS, DHS, and USDA, with no single agency or recipient dominating the aggregate. The highest-materiality award is ESA SOUTH, INC.'s $58,870,322 VA HVAC replacement contract, but its $0 recorded outlays and project-based nature leave execution unverified. The most notable wind-down signal is OptumServe Technology Services' $37,410,472 HRSA COVID-19 close-out award, consistent with declining pandemic-related federal spending. Average signal strength is low at 3.2/10 and all six signals are rated neutral, so no contract on its own supports a directional investment thesis; the key watch item is whether the zero outlay on ESA SOUTH begins to move and whether the Department of Labor Job Corps and vocational awards to CAREER SYSTEMS DEVELOPMENT and PARADIGMWORKS are recompeted or extended.

6 total filings
· daily

Significant Contract Modifications ($10M+) — October 11, 2026

Six significant contract modifications totaling $241,728,413 in obligations were recorded on October 11, 2026, with zero defense-related awards and all six classified as civilian (VA, DOL x2, HHS, DHS, USDA). The dominant themes are civilian workforce training, facility infrastructure, and government-operated or low-materiality services rather than defense spending. The highest-conviction signal is the VA award to ESA SOUTH, INC. ($58,870,322, an HVAC/infrastructure replacement with a firm-fixed-price structure and SDVOSB set-aside), though the reported $0 outlayed means execution is unverified. Average signal strength is 3.2/10 and all six signals are neutral, so no clear bullish or bearish call is supported by this batch. The key watch item is the OptumServe Technology Services, Inc. ($37,410,472) COVID-19 close-out award, which signals wind-down of pandemic-related HHS spending, and whether its option exercise and end-date changes materialize around January 2027.

6 total filings
· daily

Contract Deobligations Alert — October 11, 2026

Six federal contracts totaling $241,728,413 in obligations were reviewed, with none classified as defense-related; all six are civilian awards across the Department of Veterans Affairs, Department of Labor (two awards), HHS, DHS, and USDA. The dominant theme is civilian services and infrastructure spending rather than defense procurement, with no single agency or recipient dominating the set. Average signal strength is low at 3.2/10 and every contract is rated neutral, so no contract produces a high-conviction directional call. The largest award, ESA SOUTH, INC.'s $58,870,322 VA HVAC replacement contract, is a single project with $0 outlayed reported, making execution progress the key unknown. Watch items include whether OptumServe's COVID-19 close-out work ($31,134,054 outlayed of $37,410,472) signals a broader wind-down of pandemic-related HHS spending, and whether option exercises on the DOL Job Corps and Forest Service contracts occur on schedule.

6 total filings
· daily

Contract Option Exercises — October 11, 2026

Six contract option exercises totaling $241,728,413 in obligations were recorded on October 11, 2026, with zero defense-related awards; all six are civilian, spanning the Department of Veterans Affairs, Department of Labor (three awards), HHS/HRSA, DHS/FLETC, and USDA Forest Service. The dominant theme is civilian services and facilities work, led by a labor/training cluster in DOL Job Corps and vocational services (CAREER SYSTEMS DEVELOPMENT CORPORATION $48,973,885; PARADIGMWORKS GROUP $36,145,959). The highest-conviction signal is the USDA Forest Service exclusive-use airtanker task order to AERO-FLITE, INC. ($29,284,763 obligated against a $50,006,905 ceiling, with $23,793,528 outlayed), reflecting sustained wildfire aviation demand, though all six awards carry only neutral signal strength (average 3.2/10) and no direct public-equity exposure is confirmed for most recipients. The key watch item is the wind-down framing of OptumServe Technology Services' $37,410,472 HRSA COVID-19 close-out award, which is a bearish indicator for pandemic-response program revenue.

6 total filings
· daily

Federal Professional Services Contracts — October 11, 2026

This digest covers a single federal professional services award totaling $37,410,472 in obligations, issued on 2024-10-11 to OptumServe Technology Services, Inc., a UnitedHealth Group subsidiary. The award is entirely civilian (HHS/HRSA) with zero defense-related contracts in the period, so there is no defense/civilian split to draw conclusions from. The dominant theme is federal COVID-19 program wind-down, as the work covers close-out services for the Uninsured and Provider Relief Fund programs. The highest-conviction signal is the sole-source, not-competed nature of the award, which indicates a narrow incumbent position rather than a competitive win, while the modest scale (roughly 2.5% of the aggregate in this stream context is not applicable here, but the award is small relative to UnitedHealth Group's total revenue) limits materiality to the parent. The key watch item is whether HRSA exercises the unused options between the $37,410,472 obligation and the $43,783,168 ceiling, and whether the outlay progression from $31,134,054 continues toward completion.

1 total filings
· daily

All HHS Contracts — October 11, 2026

This digest covers a single HHS contract record totaling $37,410,472 in obligations, with zero defense-related awards, so the entire data set is civilian. The sole award went to OptumServe Technology Services, Inc., a UnitedHealth Group subsidiary, through a not-competed firm-fixed-price definitive contract from HRSA for COVID-19 Uninsured and Provider Relief Fund close-out services. The dominant theme is the wind-down of pandemic-era federal program spending, which the close-out framing suggests is in a declining phase. The highest-conviction signal is that roughly 83% of the obligation ($31,134,054) has already been outlaid, indicating the work is largely complete and the revenue run-rate is likely tapering. The key watch item is whether the unused option value (ceiling of $43,783,168 versus $37,410,472 obligated) is exercised and whether the 2027-01-11 current end date is extended.

1 total filings
· daily

High-Value Federal Grants ($5M+) — October 11, 2026

Six high-value federal grants and contracts totaling $241,728,413 were recorded for October 11, 2026, with zero defense-related awards, so the entire digest is civilian-agency exposure across VA, DOL, HHS, DHS, and USDA. The dominant themes are workforce training (two DOL Job Corps-type awards totaling roughly $85.1M in obligations), pandemic close-out wind-down (OptumServe at $37.4M), and small-scale infrastructure and services work. Average signal strength is a low 3.2/10 and all six signals are rated neutral, so no contract on its own is investable catalyst-grade. The highest-conviction observation is the bearish read-through from OptumServe Technology Services' COVID-19 close-out scope, where $31.1M of $37.4M is already outlayed, signaling declining HHS pandemic-response revenue. The key watch item is option exercise and end-date modifications across the DOL and USDA awards, which will determine whether roughly $18.3M (Paradigmworks) and $20.7M (Aero-Flite) of unobligated ceiling converts into realized revenue.

6 total filings